FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366089504> ?p ?o ?g. }

• W4366089504 endingPage "976" @default.
• W4366089504 startingPage "976" @default.
• W4366089504 abstract "Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have reduced the risk of the severe clinical progress of COVID-19. However, the risk of breakthrough infections has increased, and early administration of an effective antiviral treatment is significant in order to prevent the severe progression of COVID-19 in vulnerable patients with comorbidities.Adults with confirmed SARS-CoV-2 infection were included in a matched-pair retrospective study based on age, gender, comorbidities and vaccination status. They were divided into two groups: group A (n = 200) consisted of outpatients at increased risk of severe clinical progress who were treated with nirmatrelvir/ritonavir and group B (n = 200) consisted of non-hospitalized patients who did not receive antiviral treatment. Demographic data, clinical outcome (death, intubation), days of hospitalization, time for recovery, adverse events and treatment compliance were reported.The median age (75.24 ± 13.12 years in the study group and 76.91 ± 14.02 years in the comparison group) and the proportion of males (59% vs. 60.5%, respectively) were similar between the two groups. A total of 6.5% of patients in group A and 10.5% in group B were unvaccinated against SARS-CoV-2. Three patients from group A (1.5%) and one hundred eleven (55.5%) from group B required hospitalization. The duration of hospitalization (3 days vs. 10 days in group B, p < 0.001) and the total time needed for recovery (5 days vs. 9 days, p < 0.001) was shorter in the study group. A rebound of SARS-CoV-2 infection within 8-12 days after diagnosis was documented in 6.5% of patients in group A and 8% of patients in group B.Oral treatment with nirmatrelvir/ritonavir in high-risk non-hospitalized patients was safe and effective in preventing the severe clinical progress of COVID-19 pneumonia. Early administration of antiviral agents in vulnerable outpatients combined with a full vaccination scheme is significant in order to avoid hospitalization and severe clinical outcomes." @default.
• W4366089504 created "2023-04-19" @default.
• W4366089504 creator A5001026149 @default.
• W4366089504 creator A5001788360 @default.
• W4366089504 creator A5008628863 @default.
• W4366089504 creator A5031663617 @default.
• W4366089504 creator A5072529025 @default.
• W4366089504 date "2023-04-16" @default.
• W4366089504 modified "2023-10-14" @default.
• W4366089504 title "The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data" @default.
• W4366089504 cites W2147472643 @default.
• W4366089504 cites W2979108578 @default.
• W4366089504 cites W3014708904 @default.
• W4366089504 cites W3027630905 @default.
• W4366089504 cites W3046496943 @default.
• W4366089504 cites W3133820153 @default.
• W4366089504 cites W3154750958 @default.
• W4366089504 cites W3157860346 @default.
• W4366089504 cites W3165479483 @default.
• W4366089504 cites W3189646261 @default.
• W4366089504 cites W3193601449 @default.
• W4366089504 cites W3195990721 @default.
• W4366089504 cites W4200051875 @default.
• W4366089504 cites W4200206478 @default.
• W4366089504 cites W4210736465 @default.
• W4366089504 cites W4225248506 @default.
• W4366089504 cites W4226023710 @default.
• W4366089504 cites W4226164088 @default.
• W4366089504 cites W4226236384 @default.
• W4366089504 cites W4281988270 @default.
• W4366089504 cites W4283261856 @default.
• W4366089504 cites W4285592679 @default.
• W4366089504 cites W4286762197 @default.
• W4366089504 cites W4289654238 @default.
• W4366089504 cites W4292549392 @default.
• W4366089504 cites W4293198902 @default.
• W4366089504 cites W4298149930 @default.
• W4366089504 cites W4298326470 @default.
• W4366089504 cites W4301393853 @default.
• W4366089504 cites W4302763072 @default.
• W4366089504 cites W4303423758 @default.
• W4366089504 cites W4304117179 @default.
• W4366089504 cites W4307765497 @default.
• W4366089504 cites W4308683905 @default.
• W4366089504 cites W4308975290 @default.
• W4366089504 cites W4309604538 @default.
• W4366089504 cites W4309882530 @default.
• W4366089504 cites W4310130637 @default.
• W4366089504 cites W4313546219 @default.
• W4366089504 cites W4315436946 @default.
• W4366089504 cites W4317790541 @default.
• W4366089504 doi "https://doi.org/10.3390/v15040976" @default.
• W4366089504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37112956" @default.
• W4366089504 hasPublicationYear "2023" @default.
• W4366089504 type Work @default.
• W4366089504 citedByCount "1" @default.
• W4366089504 countsByYear W43660895042023 @default.
• W4366089504 crossrefType "journal-article" @default.
• W4366089504 hasAuthorship W4366089504A5001026149 @default.
• W4366089504 hasAuthorship W4366089504A5001788360 @default.
• W4366089504 hasAuthorship W4366089504A5008628863 @default.
• W4366089504 hasAuthorship W4366089504A5031663617 @default.
• W4366089504 hasAuthorship W4366089504A5072529025 @default.
• W4366089504 hasBestOaLocation W43660895041 @default.
• W4366089504 hasConcept C126322002 @default.
• W4366089504 hasConcept C141071460 @default.
• W4366089504 hasConcept C142462285 @default.
• W4366089504 hasConcept C167135981 @default.
• W4366089504 hasConcept C197934379 @default.
• W4366089504 hasConcept C203014093 @default.
• W4366089504 hasConcept C205545832 @default.
• W4366089504 hasConcept C22070199 @default.
• W4366089504 hasConcept C2522874641 @default.
• W4366089504 hasConcept C2777785397 @default.
• W4366089504 hasConcept C2778716859 @default.
• W4366089504 hasConcept C2779134260 @default.
• W4366089504 hasConcept C2779298103 @default.
• W4366089504 hasConcept C2780678043 @default.
• W4366089504 hasConcept C2993143319 @default.
• W4366089504 hasConcept C3008058167 @default.
• W4366089504 hasConcept C524204448 @default.
• W4366089504 hasConcept C71924100 @default.
• W4366089504 hasConceptScore W4366089504C126322002 @default.
• W4366089504 hasConceptScore W4366089504C141071460 @default.
• W4366089504 hasConceptScore W4366089504C142462285 @default.
• W4366089504 hasConceptScore W4366089504C167135981 @default.
• W4366089504 hasConceptScore W4366089504C197934379 @default.
• W4366089504 hasConceptScore W4366089504C203014093 @default.
• W4366089504 hasConceptScore W4366089504C205545832 @default.
• W4366089504 hasConceptScore W4366089504C22070199 @default.
• W4366089504 hasConceptScore W4366089504C2522874641 @default.
• W4366089504 hasConceptScore W4366089504C2777785397 @default.
• W4366089504 hasConceptScore W4366089504C2778716859 @default.
• W4366089504 hasConceptScore W4366089504C2779134260 @default.
• W4366089504 hasConceptScore W4366089504C2779298103 @default.
• W4366089504 hasConceptScore W4366089504C2780678043 @default.
• W4366089504 hasConceptScore W4366089504C2993143319 @default.
• W4366089504 hasConceptScore W4366089504C3008058167 @default.

• next